Thymalin

Approved in Russia for immune deficiency states. Long-term Khavinson studies claim lifespan extension in elderly cohorts, but these are not independently confirmed.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Russian clinical use for decades. Khavinson group published a 6-year elderly cohort study claiming reduced mortality. Methodology has been questioned. Not evaluated internationally.

• Immune-modulating effects in Russian clinical practice
• Claimed mortality reduction in elderly cohort study
• Decades of clinical use in Russia

Russian protocols: 10 mg IM daily for 5–10 days. Repeated courses every 3–6 months.

• Injection-site reactions
• Allergic reactions rare
• Theoretical autoimmune activation

Animal-derived biological. Not approved outside Russia. Product authenticity from online sources is uncertain.

The mortality reduction claim from the Khavinson cohort study is not independently replicated and has methodological concerns.

• Immunity35
• Longevity25